Skip to main content

Evaluation of the Incidence of Gastroesophageal Reflux Following Sleeve Gastrectomy with and without Omentopexy: A Double-Blind Randomized Controlled Trial

In brief

Omentopexy did not significantly reduce reflux after sleeve gastrectomy at one year

In a randomized trial of 290 patients, new reflux affected 20% with omentopexy and 26.9% without it at one year, a difference that was not statistically significant. A subgroup losing more than 50 kg had less reflux with omentopexy, but the overall result and lack of objective reflux measurements leave its protective role uncertain.

Journal
Obesity surgery (Q1)
Published
12 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Hossein Malekee, Fakhroddin Keiany, Mohammad Sadegh Fakhari, Sanaz Zand
PMID
43018867
DOI
10.1007/s11695-026-08991-w

Why clinicians should know about it

  • Picked for Surgery (top studies of the week, 15 November 2026): Randomized comparison of a sleeve gastrectomy operative technique
  • Picked for Bariatric and Metabolic Surgery (top studies of the week, 15 November 2026): Randomized trial of reflux prevention after sleeve gastrectomy

Abstract

BACKGROUND: Gastroesophageal reflux disease (GERD) is a common complication following laparoscopic sleeve gastrectomy (LSG), yet the role of omentopexy in mitigating postoperative reflux remains unclear. We conducted a double-blind, randomized controlled trial to compare the incidence of de novo GERD after LSG with and without omentopexy. METHODS: Between 2023 and 2024, 290 adult patients (BMI ≥ 30 kg/m² with comorbidities or ≥ 40 kg/m²) without preexisting GERD or significant hiatal hernia were randomized (1:1) to LSG with omentopexy (Group A, n = 145) or LSG alone (Group B, n = 145). All procedures were standardized and performed by a single surgeon. Primary outcome was the incidence of new-onset GERD at 12 months, assessed by the validated Persian GERD-Q questionnaire. Secondary analyses explored associations with demographic and weight-loss parameters. Statistical comparisons employed χ² or Fisher's exact tests, with significance set at p < 0.05. RESULTS: One year postoperatively, de novo GERD occurred in 20.0% of Group A versus 26.9% of Group B (p = 0.212). Mean weight loss trajectories were comparable, reaching ~ 44%TWL by month 12 in both arms. Subgroup analysis revealed that among patients losing > 50 kg, those in Group A exhibited a significantly lower GERD incidence compared to Group B (9.4% vs. 25.0%; p = 0.023). No significant differences emerged by age, sex, or endoscopic findings. CONCLUSIONS: Omentopexy performed during LSG did not significantly reduce overall de novo GERD incidence at one year, although a trend toward benefit and a significant effect in patients with substantial weight loss were observed. Further large-scale trials incorporating objective reflux measurements are warranted to clarify the potential protective role of omental fixation in bariatric practice.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.